Alzheimer's Disease: Symptoms, Diagnosis, and Treatment

Summary

Alzheimer’s disease is the most common cause of dementia and a leading cause of disability in older adults. It is a progressive neurodegenerative condition caused by abnormal protein accumulation in the brain, leading to gradual loss of memory, thinking, and eventually the ability to carry out daily activities.

This guide covers:

What Alzheimer’s disease is and how it differs from dementia
Early symptoms and how the disease progresses
Risk factors — modifiable and non-modifiable
How diagnosis is made, including the role of biomarkers
Current treatments and the emerging field of disease-modifying therapies
Practical considerations for people living with the disease and their caregivers
Prognosis and what to expect over time

What Is Alzheimer’s Disease?

Alzheimer’s disease is a neurodegenerative condition characterised by the accumulation of two abnormal proteins in the brain: amyloid plaques (aggregates of amyloid-beta protein that build up between neurons) and tau tangles (twisted filaments of tau protein that form inside neurons). Together, these changes disrupt communication between brain cells, trigger inflammation, and lead to progressive neuronal death.

The brain regions most affected first are those involved in memory formation — particularly the hippocampus — which explains why memory problems are typically the earliest and most prominent symptom. Over time, the disease spreads to regions responsible for language, spatial navigation, executive function, and eventually movement and basic bodily functions.

Alzheimer’s disease develops over years or decades before symptoms appear. The biological changes (amyloid accumulation in particular) can begin 15–20 years before any memory complaints. This long preclinical phase is now a focus of early detection and intervention research.

Alzheimer’s Disease and Dementia

Dementia is not a disease — it is a syndrome. It refers to a cluster of symptoms significant enough to interfere with daily life: memory loss, difficulties with language, impaired reasoning, disorientation, and changes in behaviour or personality.

Alzheimer’s disease causes approximately 60–70% of all dementia cases, making it the most common underlying cause. Other diseases that cause dementia include:

Vascular dementia — caused by strokes or reduced blood flow to the brain
Lewy body dementia — caused by alpha-synuclein protein deposits, often with visual hallucinations and movement features
Frontotemporal dementia — predominantly affects personality, behaviour, and language
Mixed dementia — more than one pathology present simultaneously (common in older adults)

Understanding this distinction matters: a diagnosis of “dementia” is a description of the syndrome, not the cause. Identifying the underlying disease (such as Alzheimer’s) requires further investigation and shapes prognosis and treatment.

Early Symptoms

The most characteristic early symptom of Alzheimer’s disease is short-term memory impairment — difficulty encoding and retrieving recent information, while older memories remain relatively intact. This is distinct from the normal age-related memory lapses that most people experience.

Typical early warning signs include:

Repeatedly asking the same question or telling the same story within a short period
Forgetting recent conversations, appointments, or events
Misplacing objects in unusual places (for example, putting keys in the refrigerator) and being unable to retrace steps to find them
Becoming lost in familiar places
Difficulty with complex tasks involving planning, problem-solving, or multi-step instructions
Word-finding difficulties — struggling to name common objects or losing track of what they were saying mid-sentence
Changes in mood or personality — increased anxiety, withdrawal, suspicion, or irritability

Many people with early Alzheimer’s disease are aware that something is wrong and experience significant distress or anxiety as a result. Conversely, a characteristic feature as the disease progresses is anosognosia — reduced awareness of one’s own cognitive difficulties.

How Alzheimer’s Disease Progresses

Alzheimer’s disease progresses through a continuum rather than discrete, clearly defined stages. Clinical frameworks typically describe three broad phases:

Mild (Early-Stage)

Daily function is largely preserved, but memory and other cognitive symptoms are noticeable. The person may manage most activities independently but struggle with complex tasks such as managing finances, keeping appointments, or following complicated instructions. This phase can last several years.

Moderate (Middle-Stage)

Memory and cognitive impairment become more significant. The person may need assistance with some activities of daily living (dressing, bathing, preparing meals) and may become disoriented about time or place. Behavioural and psychological symptoms — including agitation, depression, sleep disturbance, and occasionally hallucinations or paranoid thinking — are common in this phase. This is typically the longest phase of the disease.

Severe (Late-Stage)

The person loses the ability to carry out basic functions independently. Communication becomes severely limited. The individual requires full assistance with personal care and is often bed-bound in the final stages. Swallowing difficulties, susceptibility to infections, and loss of bladder and bowel control are features of advanced disease.

The rate of progression varies considerably between individuals and is influenced by age at diagnosis, overall health, vascular risk factors, and the presence of other comorbidities.

Risk Factors

Non-Modifiable Risk Factors

Age — the single strongest risk factor. Alzheimer’s disease affects approximately 1 in 14 people over 65 and 1 in 6 people over 80. Age does not cause Alzheimer’s disease, but the underlying biology accumulates over decades.
Genetics — a family history of Alzheimer’s increases risk. The APOE ε4 allele is the most significant genetic risk factor in the general population; having one copy increases risk moderately, two copies substantially. Rare autosomal dominant mutations in APP, PSEN1, and PSEN2 genes cause inherited early-onset Alzheimer’s disease, which is uncommon.
Sex — Alzheimer’s disease is more common in women, likely reflecting both longer life expectancy and hormonal factors.
Down syndrome — people with Down syndrome carry an extra copy of chromosome 21 (where the APP gene resides) and have a very high lifetime risk of developing Alzheimer’s disease pathology.

Modifiable Risk Factors

Evidence from the Lancet Commission on Dementia Prevention (2024) identifies multiple modifiable factors associated with risk. These represent opportunities for prevention across the lifespan:

High blood pressure — particularly in midlife, is among the most important modifiable risk factors
Physical inactivity — regular aerobic exercise is consistently associated with reduced Alzheimer’s risk and slower cognitive decline
Poor sleep — chronic sleep deprivation impairs the glymphatic system’s clearance of amyloid-beta from the brain
Head injury — particularly repeated mild traumatic brain injury
Hearing loss — untreated hearing loss in midlife significantly increases dementia risk
Smoking
Excessive alcohol
Air pollution
Social isolation — limited social engagement is associated with faster cognitive decline
Low educational attainment — linked to lower cognitive reserve
Depression — whether as a risk factor or early symptom remains debated; treatment is important regardless
Obesity and metabolic risk — diabetes, high cholesterol, and obesity in midlife increase vascular contributions to cognitive impairment

Addressing multiple risk factors simultaneously offers greater protective benefit than focusing on any single factor.

Diagnosis

There is no single test that diagnoses Alzheimer’s disease. Diagnosis involves a structured clinical process:

Clinical History

A detailed account of symptoms from the person and, critically, a family member or close contact who can describe changes over time. The clinician will want to know: what changed, when it started, how quickly it has progressed, and how it affects daily function.

Cognitive Assessment

Standardised tools — such as the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), or Addenbrooke’s Cognitive Examination (ACE-III) — provide a quantifiable snapshot of memory, language, attention, and executive function. Neuropsychological testing provides a more detailed profile when needed.

Neurological Examination

Assessing for other neurological signs, focal deficits, or features of Parkinson’s disease or other conditions that could account for cognitive symptoms.

Blood Tests

Used to exclude reversible causes of cognitive impairment — including thyroid dysfunction, B12 or folate deficiency, kidney or liver disease, diabetes, depression, and medication effects. These are treatable causes that must be ruled out.

Brain Imaging

CT or MRI brain scanning can identify structural changes consistent with Alzheimer’s disease (particularly hippocampal and medial temporal lobe atrophy), rule out other causes (stroke, tumour, normal pressure hydrocephalus), and help distinguish between dementia subtypes. Advanced imaging — including amyloid PET scans — can directly visualise amyloid pathology but is primarily used in specialist research and selected clinical settings.

Biomarker Testing

See the section below.

Biomarkers

Biomarkers allow clinicians to identify the underlying biological features of Alzheimer’s disease rather than relying solely on clinical assessment. This is increasingly important as disease-modifying therapies require confirmation of amyloid pathology before treatment.

Key biomarker types:

Cerebrospinal fluid (CSF) biomarkers — a lumbar puncture measures amyloid-beta 42, total tau, and phosphorylated tau in CSF. Abnormal ratios support a diagnosis of Alzheimer’s pathology with high accuracy.
Amyloid PET imaging — a specialised brain scan that directly detects amyloid deposits. Requires access to specialist imaging centres and is not available as a routine investigation in most health systems.
Blood-based biomarkers — plasma p-tau217 (and other phosphorylated tau variants) have emerged as accurate, less invasive markers that can support diagnostic workup in appropriate clinical settings. These are increasingly used in specialist memory services. They reflect amyloid and tau pathology with good sensitivity and specificity but require clinical interpretation alongside symptoms and cognitive testing.

Modern diagnostic frameworks (including the 2024 Alzheimer’s Association criteria) conceptualise Alzheimer’s as a clinical-biological condition. A positive biomarker result in the absence of symptoms does not mean a person has Alzheimer’s disease that requires treatment — clinical judgement, symptoms, and stage all inform management decisions.

Treatment Options

Symptom-Focused Medications

Two classes of medication are established for managing cognitive symptoms in Alzheimer’s disease:

Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) — inhibit the breakdown of acetylcholine, a neurotransmitter that is progressively depleted in Alzheimer’s disease. They provide modest symptomatic benefit for cognition and daily function in mild to moderate disease. Side effects include nausea, diarrhoea, and vivid dreams.

Memantine — an NMDA receptor antagonist used in moderate to severe Alzheimer’s disease, alone or in combination with acetylcholinesterase inhibitors. It may reduce agitation and improve function modestly.

These medications do not alter the underlying disease course — they manage symptoms while the disease continues to progress. Not everyone responds, and the degree of benefit varies. The decision to start or continue medication should be guided by a specialist with input from the person and their family.

Non-Pharmacological Management

Non-pharmacological approaches are important at all stages:

Cognitive stimulation — structured cognitive engagement activities are associated with improved quality of life
Physical activity — regular exercise may slow functional decline and reduces vascular risk
Management of behavioural and psychological symptoms — structured assessment, communication approaches, and environmental modifications often reduce distress more safely than medication
Vascular risk factor management — treating blood pressure, diabetes, and high cholesterol is beneficial regardless of disease stage and may slow vascular contributions to decline
Practical and safety supports — memory aids, safe home environment, driving assessment, advance care planning

Managing Behavioural and Psychological Symptoms

Anxiety, depression, agitation, sleep disturbance, and occasionally psychotic symptoms (hallucinations, delusions) are common, particularly in moderate to severe Alzheimer’s disease. Non-pharmacological strategies are first-line for most behavioural symptoms. Medications (antidepressants, low-dose antipsychotics in specific situations) are sometimes necessary but carry risks in older adults and should be used cautiously and with regular review.

New and Emerging Therapies

The past decade has seen the first disease-modifying therapies for early Alzheimer’s disease reach regulatory approval:

Lecanemab (Leqembi) — a monoclonal antibody targeting amyloid-beta protofibrils. Clinical trials demonstrated a statistically significant slowing of clinical decline (approximately 27% slowing over 18 months) compared to placebo in people with early Alzheimer’s disease with confirmed amyloid pathology. Approved by the FDA in 2023 (full approval) and under review in other jurisdictions.

Donanemab — a monoclonal antibody targeting a modified form of amyloid-beta. Trial results showed similar magnitude effects on clinical progression in early Alzheimer’s disease. Regulatory approval in process.

Important context for these therapies:

They are eligible only for people with early Alzheimer’s disease (mild cognitive impairment or mild dementia stage) with confirmed amyloid pathology on biomarker testing
They require intravenous infusion and intensive monitoring for amyloid-related imaging abnormalities (ARIA) — a potentially serious side effect involving brain swelling or microhaemorrhages
The absolute magnitude of benefit, while statistically significant, is modest on clinical scales. Not all individuals experience meaningful benefit
They are not available in most public health systems; cost, access, and eligibility criteria are significant practical barriers
They do not cure or reverse Alzheimer’s disease; they slow progression in appropriately selected early-stage patients

For the majority of people living with Alzheimer’s disease — particularly those in moderate or advanced stages — current treatment remains symptom-focused and supportive, not disease-modifying.

Caregiver Considerations

The impact of Alzheimer’s disease on family members and caregivers is profound and often underestimated. The majority of care for people with Alzheimer’s disease is provided by unpaid family members, and caregiver burden — including depression, anxiety, social isolation, and physical health problems — is well documented.

Key considerations for families and caregivers:

Seek information early — understanding the disease, its progression, and available services allows for planning before crises arise
Legal and financial planning — while the person retains decision-making capacity, discussing and establishing enduring power of attorney, advance care directives, and financial arrangements reduces future stress
Driving — Alzheimer’s disease inevitably affects driving safety. Assessment and, when necessary, cessation of driving is an important safety matter. This is a sensitive topic that often requires clinical input
Home safety — as cognition declines, home modifications (removing trip hazards, securing medications, adding alarms for doors) reduce accident risk
Respite and support services — day programs, in-home support, and carer support organisations can reduce isolation and provide practical assistance
Caregiver wellbeing — maintaining one’s own health is not optional; caregiver breakdown leads to worse outcomes for everyone. Peer support, counselling, and regular health check-ups for caregivers should not be deferred
Advance care planning — discussions about future medical care preferences, including resuscitation and hospitalisation in late-stage disease, are important to have early and document formally

For a comprehensive guide to practical caregiving — including home safety, daily routines, medication safety, and caregiver burnout — see: Dementia Caregiving: Safety, Support, and Planning

Prognosis

Alzheimer’s disease is progressive and currently irreversible. Life expectancy after diagnosis varies considerably:

Average survival from diagnosis is 8–10 years, though ranges of 3–20 years are reported depending on age at diagnosis, overall health, and stage at detection
Younger age at diagnosis tends to be associated with longer survival but more years of disability
Death is most commonly caused by complications of advanced disease — aspiration pneumonia, infections, or cardiovascular events — rather than the neurological disease itself

Prognosis is not a fixed number. The rate of progression differs substantially between individuals, and supportive management genuinely affects quality of life and caregiver wellbeing even when disease course cannot be altered.

Early diagnosis, while emotionally difficult, allows more time for planning, participation in treatment decisions, access to clinical trials, and optimising the years of preserved function.

When to Seek Medical Review

Consult your doctor if you or someone you know experiences:

Memory problems that are getting progressively worse rather than remaining stable
Repeatedly asking the same questions or repeating the same stories within a short period
Getting lost in familiar places
Difficulty managing finances, medications, or multi-step tasks that were previously routine
Unexplained personality or mood changes, particularly in someone over 60
Word-finding difficulties more pronounced than occasional age-related lapses

Early assessment is important — many reversible causes of memory problems exist and should be excluded, and early diagnosis enables planning and access to support.

FAQ

Is Alzheimer’s disease the same as dementia?

No. Dementia is a syndrome — a set of symptoms affecting memory, thinking, and daily function. Alzheimer’s disease is a specific disease and the most common cause of dementia, accounting for 60–70% of cases. Other diseases can also cause the dementia syndrome.

What are the very first signs of Alzheimer’s disease?

The most characteristic early sign is short-term memory impairment — difficulty remembering recent events or conversations while retaining older memories. Other early signs include repeating questions, misplacing objects in unusual places, word-finding difficulties, and subtle changes in mood or personality.

Can a blood test diagnose Alzheimer’s disease?

Blood-based biomarkers (particularly plasma p-tau217) can support the diagnostic workup but require integration with clinical history, cognitive assessment, and sometimes imaging. Interpretation requires clinical input — a blood test result should not be considered in isolation.

What is the difference between Alzheimer’s and normal ageing?

Normal ageing may involve occasional word-finding lapses and slower processing. Alzheimer’s disease involves progressive decline that disrupts daily function — repeatedly asking the same question within minutes, getting lost in familiar places, or being unable to manage previously routine tasks.

Are there treatments that slow or stop Alzheimer’s disease?

Anti-amyloid therapies (lecanemab and donanemab) have shown modest slowing of clinical decline in early-stage Alzheimer’s disease in clinical trials. For most people with Alzheimer’s disease — particularly in moderate or advanced stages — current management focuses on symptom treatment, safety, and quality of life.

What can reduce the risk of Alzheimer’s disease?

No single intervention guarantees prevention. The strongest evidence supports regular physical exercise, treating high blood pressure, adequate sleep, not smoking, managing hearing loss, social engagement, controlling diabetes and cholesterol, and a Mediterranean or MIND-style diet.

Can someone with Alzheimer’s disease live at home?

Many people with mild to moderate Alzheimer’s disease live at home with appropriate supports. As care needs increase, higher levels of support or residential care may become necessary. The right arrangement depends on the individual’s situation, available support, and safety.